Fulgent Genetics (FLGT) Financials: History & Chart

Fulgent Genetics, Inc.(FLGT)

Medical - Diagnostics & Research · El Monte, CA

$21.16-1.29 (-5.75%)

Delayed quote: Oct 6, 2026, 10:55 AM EDT

About Fulgent Genetics, Inc.

Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.

El Monte, CA

1,315 employees

www.fulgentgenetics.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Ming Hsieh

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	323.93M	85.39M	71.14M	83.34M	84.07M	81.80M	73.46M	76.21M	71.74M
Cost of Goods Sold	208.67M	59.71M	49.65M	50.75M	48.56M	47.37M	45.12M	44.37M	44.97M
Gross Profit	115.26M	25.68M	21.49M	32.58M	35.51M	34.44M	28.35M	31.85M	26.77M
Gross Profit Margin	35.6%	30.1%	30.2%	39.1%	42.2%	42.1%	38.6%	41.8%	37.3%
Total Operating Expenses	235.37M	59.58M	56.11M	68.82M	50.86M	54.15M	48.14M	47.98M	43.85M
Research & Development	56.76M	14.55M	14.18M	14.17M	13.86M	13.48M	12.39M	12.11M	11.78M
Selling, General & Administrative	169.93M	42.42M	39.91M	52.62M	34.98M	38.68M	33.76M	33.88M	30.07M
Operating Income (EBIT)	-120.11M	-33.90M	-34.62M	-36.24M	-15.35M	-19.71M	-19.80M	-16.14M	-17.08M
Operating Margin	-37.1%	-39.7%	-48.7%	-43.5%	-18.3%	-24.1%	-26.9%	-21.2%	-23.8%
Income Before Tax (EBT)	-91.08M	-29.69M	-25.98M	-29.27M	-6.14M	-21.52M	-11.72M	-8.04M	-18.53M
Interest Income	29.86M	6.40M	8.65M	6.94M	7.87M	8.09M	8.02M	8.29M	8.09M
Interest Expense	238K	59K	17K	134K	28K	17K	14K	210K	14K
Other Income/Expense	29.03M	4.21M	8.64M	6.96M	9.21M	-1.81M	8.07M	8.09M	-1.45M
Net Income	-84.38M	-29.53M	-24.83M	-23.42M	-6.61M	-18.96M	-11.53M	-5.89M	-14.65M
Income Tax Expense	-5.62M	29K	-704K	-5.62M	683K	-2.26M	176K	-1.85M	-3.84M
Net Profit Margin	-26.0%	-34.6%	-34.9%	-28.1%	-7.9%	-23.2%	-15.7%	-7.7%	-20.4%
EBITDA	-94.28M	-26.23M	-28.62M	-30.13M	-9.31M	-13.66M	-13.88M	-9.94M	-11.16M
EBITDA Margin	-29.1%	-30.7%	-40.2%	-36.2%	-11.1%	-16.7%	-18.9%	-13.0%	-15.6%
Depreciation & Amortization	25.83M	7.68M	6.00M	6.11M	6.04M	6.05M	5.92M	6.19M	5.92M
EPS Basic	-2.82	-1.05	-0.80	-0.76	-0.21	-0.61	-0.37	-0.19	-0.48
EPS Diluted	-2.82	-1.05	-0.80	-0.76	-0.21	-0.61	-0.37	-0.19	-0.48
Weighted Average Basic Shares	28.00M	28.00M	30.88M	30.78M	30.75M	30.83M	30.83M	30.65M	30.42M
Weighted Average Diluted Shares	28.00M	28.00M	30.88M	30.78M	30.75M	30.83M	30.83M	30.65M	30.42M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	322.67M	283.47M	289.21M	618.97M	992.58M	421.71M	32.53M	21.36M
Cost of Goods Sold	191.80M	176.25M	184.76M	252.07M	215.53M	89.81M	14.11M	10.69M
Gross Profit	130.88M	107.22M	104.46M	366.90M	777.05M	331.90M	18.42M	10.66M
Gross Profit Margin	40.6%	37.8%	36.1%	59.3%	78.3%	78.7%	56.6%	49.9%
Total Operating Expenses	221.97M	181.13M	299.99M	188.37M	101.10M	41.75M	18.85M	15.72M
Research & Development	53.91M	48.82M	41.44M	28.91M	24.22M	11.58M	6.54M	5.53M
Selling, General & Administrative	160.03M	124.35M	130.47M	149.99M	75.17M	30.17M	12.31M	10.19M
Operating Income (EBIT)	-91.10M	-73.92M	-195.53M	178.53M	675.95M	290.16M	-428K	-5.07M
Operating Margin	-28.2%	-26.1%	-67.6%	28.8%	68.1%	68.8%	-1.3%	-23.7%
Income Before Tax (EBT)	-70.03M	-51.96M	-174.09M	184.03M	681.03M	286.84M	-368K	-4.64M
Interest Income	30.92M	31.30M	21.61M	5.62M	1.35M	1.53M	837K	434K
Interest Expense	75K	170K	488K	1.01M	N/A	N/A	N/A	N/A
Other Income/Expense	21.07M	21.96M	21.44M	5.50M	5.08M	-3.32M	60K	434K
Net Income	-60.51M	-42.71M	-167.82M	143.40M	507.36M	214.31M	-411K	-5.61M
Income Tax Expense	-8.39M	-8.14M	1.15M	42.10M	174.79M	72.53M	43K	36K
Net Profit Margin	-18.8%	-15.1%	-58.0%	23.2%	51.1%	50.8%	-1.3%	-26.3%
EBITDA	-66.97M	-48.99M	-169.39M	211.19M	686.96M	293.12M	1.68M	-2.91M
EBITDA Margin	-20.8%	-17.3%	-58.6%	34.1%	69.2%	69.5%	5.2%	-13.6%
Depreciation & Amortization	24.12M	24.93M	26.14M	32.66M	11.00M	2.96M	2.11M	2.16M
EPS Basic	-1.97	-1.41	-5.63	4.76	17.13	9.44	-0.02	-0.25
EPS Diluted	-1.97	-1.41	-5.63	4.63	16.26	8.91	-0.02	-0.25
Weighted Average Basic Shares	30.78M	30.23M	29.78M	30.10M	29.41M	22.69M	18.71M	17.98M
Weighted Average Diluted Shares	30.78M	30.23M	29.78M	30.96M	30.98M	24.06M	18.71M	17.98M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.